PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Merck & Co., Inc. (MRK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US58933Y1055

CUSIP

58933Y105

Sector

Healthcare

IPO Date

Jan 13, 1978

Highlights

Market Cap

$253.12B

EPS (TTM)

$4.78

PE Ratio

20.93

PEG Ratio

0.07

Total Revenue (TTM)

$63.22B

Gross Profit (TTM)

$47.97B

EBITDA (TTM)

$20.41B

Year Range

$93.73 - $132.67

Target Price

$129.97

Short %

1.30%

Short Ratio

2.70

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
MRK vs. PFE MRK vs. NVO MRK vs. BMY MRK vs. VOO MRK vs. ABBV MRK vs. SCHD MRK vs. AMGN MRK vs. AAPL MRK vs. VHT MRK vs. VTIP
Popular comparisons:
MRK vs. PFE MRK vs. NVO MRK vs. BMY MRK vs. VOO MRK vs. ABBV MRK vs. SCHD MRK vs. AMGN MRK vs. AAPL MRK vs. VHT MRK vs. VTIP

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Merck & Co., Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%JulyAugustSeptemberOctoberNovemberDecember
-22.12%
7.20%
MRK (Merck & Co., Inc.)
Benchmark (^GSPC)

Returns By Period

Merck & Co., Inc. had a return of -6.22% year-to-date (YTD) and -2.96% in the last 12 months. Over the past 10 years, Merck & Co., Inc. had an annualized return of 9.17%, while the S&P 500 had an annualized return of 10.96%, indicating that Merck & Co., Inc. did not perform as well as the benchmark.


MRK

YTD

-6.22%

1M

3.91%

6M

-22.12%

1Y

-2.96%

5Y*

5.84%

10Y*

9.17%

^GSPC (Benchmark)

YTD

23.00%

1M

-0.84%

6M

7.20%

1Y

24.88%

5Y*

12.77%

10Y*

10.96%

Monthly Returns

The table below presents the monthly returns of MRK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202410.79%5.27%4.43%-2.07%-2.85%-0.80%-8.62%4.70%-3.49%-9.90%-0.66%-6.22%
2023-3.19%-1.09%0.84%8.53%-4.38%5.21%-7.57%2.18%-4.89%-0.24%-0.21%7.15%1.01%
20226.32%-6.01%8.10%8.09%3.77%-0.12%-2.01%-4.45%1.70%17.51%8.81%1.42%49.42%
2021-5.78%-5.77%7.09%-3.36%1.87%8.32%-1.16%-0.75%-0.66%17.23%-14.92%3.28%1.75%
2020-6.06%-10.39%1.33%3.12%1.74%-3.44%3.76%6.27%-2.01%-9.33%6.89%2.56%-7.20%
2019-2.59%9.22%3.01%-5.36%0.64%6.56%-1.03%4.19%-2.00%2.95%0.60%5.04%22.27%
20185.30%-8.49%1.34%8.08%1.12%2.75%8.52%4.13%4.13%3.76%7.78%-3.02%39.95%
20175.30%6.26%-2.84%-1.90%4.46%-0.84%-0.33%-0.03%0.99%-13.96%0.33%2.68%-1.49%
2016-4.07%-0.91%6.30%3.65%2.59%3.24%1.82%7.04%0.12%-5.91%4.21%-3.05%15.05%
20156.15%-2.89%-1.02%3.62%2.23%-5.79%3.57%-8.67%-7.49%10.67%-3.02%0.50%-3.89%
20145.83%7.59%0.39%3.15%-1.20%0.74%-1.92%5.94%-0.66%-2.26%4.25%-5.27%16.93%
20135.64%-1.20%4.44%6.33%-0.64%0.38%3.70%-1.83%1.58%-5.29%10.51%1.35%26.83%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of MRK is 37, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of MRK is 3737
Overall Rank
The Sharpe Ratio Rank of MRK is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of MRK is 3232
Sortino Ratio Rank
The Omega Ratio Rank of MRK is 3232
Omega Ratio Rank
The Calmar Ratio Rank of MRK is 4040
Calmar Ratio Rank
The Martin Ratio Rank of MRK is 4242
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Merck & Co., Inc. (MRK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for MRK, currently valued at -0.19, compared to the broader market-4.00-2.000.002.00-0.191.83
The chart of Sortino ratio for MRK, currently valued at -0.12, compared to the broader market-4.00-2.000.002.004.00-0.122.46
The chart of Omega ratio for MRK, currently valued at 0.98, compared to the broader market0.501.001.502.000.981.34
The chart of Calmar ratio for MRK, currently valued at -0.15, compared to the broader market0.002.004.006.00-0.152.72
The chart of Martin ratio for MRK, currently valued at -0.33, compared to the broader market0.0010.0020.00-0.3311.89
MRK
^GSPC

The current Merck & Co., Inc. Sharpe ratio is -0.19. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Merck & Co., Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.19
1.83
MRK (Merck & Co., Inc.)
Benchmark (^GSPC)

Dividends

Dividend History

Merck & Co., Inc. provided a 3.14% dividend yield over the last twelve months, with an annual payout of $3.12 per share. The company has been increasing its dividends for 19 consecutive years.


2.40%2.60%2.80%3.00%3.20%3.40%$0.00$0.50$1.00$1.50$2.00$2.50$3.0020132014201520162017201820192020202120222023
Dividends
Dividend Yield
PeriodTTM20232022202120202019201820172016201520142013
Dividend$3.12$2.96$2.80$2.61$2.37$2.16$1.90$1.80$1.77$1.73$1.69$1.65

Dividend yield

3.14%2.72%2.52%3.41%3.03%2.48%2.60%3.36%3.14%3.43%3.12%3.46%

Monthly Dividends

The table displays the monthly dividend distributions for Merck & Co., Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$0.00$0.00$0.77$0.00$0.00$0.77$0.00$0.00$0.77$0.00$0.00$0.81$3.12
2023$0.00$0.00$0.73$0.00$0.00$0.73$0.00$0.00$0.73$0.00$0.00$0.77$2.96
2022$0.00$0.00$0.69$0.00$0.00$0.69$0.00$0.00$0.69$0.00$0.00$0.73$2.80
2021$0.00$0.00$0.62$0.00$0.00$0.65$0.00$0.00$0.65$0.00$0.00$0.69$2.61
2020$0.00$0.00$0.58$0.00$0.00$0.58$0.00$0.00$0.58$0.00$0.00$0.62$2.37
2019$0.00$0.00$0.52$0.00$0.00$0.52$0.00$0.00$0.52$0.00$0.00$0.58$2.16
2018$0.00$0.00$0.46$0.00$0.00$0.46$0.00$0.00$0.46$0.00$0.00$0.52$1.90
2017$0.00$0.00$0.45$0.00$0.00$0.45$0.00$0.00$0.45$0.00$0.00$0.46$1.80
2016$0.00$0.00$0.44$0.00$0.00$0.44$0.00$0.00$0.44$0.00$0.00$0.45$1.77
2015$0.00$0.00$0.43$0.00$0.00$0.43$0.00$0.00$0.43$0.00$0.00$0.44$1.73
2014$0.00$0.00$0.42$0.00$0.00$0.42$0.00$0.00$0.42$0.00$0.00$0.43$1.69
2013$0.41$0.00$0.00$0.41$0.00$0.00$0.41$0.00$0.00$0.42$1.65

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%20.0%3.1%
Merck & Co., Inc. has a dividend yield of 3.14%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%52.4%
Merck & Co., Inc. has a payout ratio of 52.44%, which is quite average when compared to the overall market. This suggests that Merck & Co., Inc. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-24.05%
-3.66%
MRK (Merck & Co., Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Merck & Co., Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Merck & Co., Inc. was 68.62%, occurring on Mar 9, 2009. Recovery took 1239 trading sessions.

The current Merck & Co., Inc. drawdown is 24.05%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-68.62%Dec 29, 20002057Mar 9, 20091239Feb 7, 20143296
-47.25%Jan 6, 1992408Aug 13, 1993494Jul 28, 1995902
-36.5%Mar 23, 1999243Mar 7, 2000160Oct 23, 2000403
-35.02%Jun 10, 1981299Aug 13, 1982236Jul 20, 1983535
-32.79%Sep 4, 198795Jan 20, 1988332May 12, 1989427

Volatility

Volatility Chart

The current Merck & Co., Inc. volatility is 6.51%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%JulyAugustSeptemberOctoberNovemberDecember
6.51%
3.62%
MRK (Merck & Co., Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Merck & Co., Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Merck & Co., Inc. compared to its peers in the Drug Manufacturers - General industry.


PE Ratio
200.0400.0600.0800.01,000.020.9
The chart displays the price to earnings (P/E) ratio for MRK in comparison to other companies of the Drug Manufacturers - General industry. Currently, MRK has a PE value of 20.9. This PE ratio falls in the average range for the industry.
PEG Ratio
10.020.030.00.1
The chart displays the price to earnings to growth (PEG) ratio for MRK in comparison to other companies of the Drug Manufacturers - General industry. Currently, MRK has a PEG value of 0.1. This PEG value is considered to be low compared to the rest of the industry.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Merck & Co., Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab